STERIS’s (STE) “Market Outperform” Rating Reiterated at JMP Securities

STERIS (NYSE:STE)‘s stock had its “market outperform” rating reiterated by stock analysts at JMP Securities in a note issued to investors on Thursday,Benzinga reports. They presently have a $265.00 price target on the medical equipment provider’s stock. JMP Securities’ price objective would suggest a potential upside of 17.55% from the company’s previous close.

A number of other analysts also recently commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a report on Friday, November 8th. Stephens restated an “overweight” rating and issued a $240.00 price target on shares of STERIS in a report on Thursday. StockNews.com cut STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. Finally, Piper Sandler boosted their price objective on shares of STERIS from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, STERIS currently has a consensus rating of “Moderate Buy” and a consensus target price of $258.75.

STERIS Stock Up 2.1 %

NYSE:STE traded up $4.60 during midday trading on Thursday, hitting $225.43. 546,282 shares of the company were exchanged, compared to its average volume of 478,538. STERIS has a fifty-two week low of $197.82 and a fifty-two week high of $248.24. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $22.25 billion, a PE ratio of 51.38 and a beta of 0.84. The company has a fifty day simple moving average of $212.33 and a 200 day simple moving average of $224.59.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a net margin of 8.02% and a return on equity of 13.78%. As a group, equities analysts anticipate that STERIS will post 9.11 earnings per share for the current fiscal year.

Insider Transactions at STERIS

In related news, SVP Cary L. Majors sold 1,682 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the transaction, the senior vice president now directly owns 11,372 shares in the company, valued at $2,471,363.04. The trade was a 12.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.14% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On STERIS

Hedge funds have recently made changes to their positions in the company. Ashton Thomas Securities LLC acquired a new position in STERIS during the 3rd quarter worth about $25,000. Human Investing LLC bought a new position in shares of STERIS in the fourth quarter worth about $31,000. Anfield Capital Management LLC lifted its position in shares of STERIS by 100.0% during the fourth quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 91 shares in the last quarter. Central Pacific Bank Trust Division grew its stake in shares of STERIS by 65.5% during the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 76 shares during the last quarter. Finally, Manchester Capital Management LLC increased its holdings in shares of STERIS by 182.7% in the fourth quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 137 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.